Journal article
A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191
Authors
Hay AE; Murugesan A; DiPasquale AM; Kouroukis T; Sandhu I; Kukreti V; Bahlis NJ; Lategan J; Reece DE; Lyons JF
Journal
Leukemia & Lymphoma, Vol. 57, No. 6, pp. 1463–1466
Publisher
Taylor & Francis
Publication Date
June 2, 2016
DOI
10.3109/10428194.2015.1091927
ISSN
1042-8194